TFRC and colonic neoplasm: Sardoiwala et al. (2020) synthesized hypericin-loaded transferrin nanoparticles with the size range of ∼65 ± 5 nm and aimed to target transferrin receptor in three different colon cancer cells {Caco2 [low expression of CD71 (transferrin receptor)], SW480, and HCT116 cells [higher expression of CD71 (transferrin receptor)]}.